A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients

Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posacon...

Full description

Bibliographic Details
Main Authors: Bettina Gerner, Fatemeh Aghai-Trommeschlaeger, Sabrina Kraus, Götz Ulrich Grigoleit, Sebastian Zimmermann, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceutics
Subjects:
physiologically based pharmacokinetic (PBPK) modeling
ruxolitinib
posaconazole
drug–drug interactions (DDIs)
graft versus host disease
cytochrome P450 3A4 (CYP3A4)
Online Access:https://www.mdpi.com/1999-4923/14/12/2556

Internet

https://www.mdpi.com/1999-4923/14/12/2556

Similar Items